CELU241220C7500
- 0.40
- 0.000.00%
Celularity Newsroom
Celularity (CELU) Gets a Buy From H.C. Wainwright
Analysts' Opinions Are Mixed on These Services Stocks: Celularity (CELU) and Madison Square Garden Entertainment (MSGE)
HC Wainwright Lowers Price Target on Celularity to $2.50 From $15, Maintains Buy Rating
Celularity Analyst Ratings
HC Wainwright & Co. Maintains Buy on Celularity, Lowers Price Target to $2.5
H.C. Wainwright Sticks to Its Buy Rating for Celularity (CELU)
Celularity Analyst Ratings
Oppenheimer Adjusts Celularity Price Target to $6 From $8, Maintains Outperform Rating
Morgan Stanley Trims Celularity's Price Target to $5 From $8, Keeps Equalweight Rating
HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here
Celularity Is Maintained at Equal-Weight by Morgan Stanley
Celularity Price Target Cut to $5.00/Share From $8.00 by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Celularity, Lowers Price Target to $5
Celularity Analyst Ratings
Celularity Analyst Ratings
Alliance Global Partners Initiates Coverage on Celularity With Buy Rating, $15 Price Target
Celularity Is Maintained at Hold by Truist Securities
Truist Securities Trims Price Target on Celularity to $6 From $10, Reiterates Hold Rating
Celularity Analyst Ratings
Truist Securities Maintains Hold on Celularity, Lowers Price Target to $6